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Abstract 
Background: It is unclear what to do when people with type 2 diabetes have had no or a 
limited glycemic response to a recently introduced medication. Intra-individual HbA1c 
variability can obscure true response. Some guidelines suggest stopping apparently 
ineffective therapy, but no studies have addressed this issue. 
Methods: In a retrospective cohort analysis using the UK Clinical Practice Research Datalink 
(CPRD), we assessed the outcome of 55,530 patients with type 2 diabetes starting their 
second or third non-insulin glucose lowering medication, with a baseline HbA1c >58mmol/mol 
(7.5%).  For those with no HbA1c improvement or a limited response at 6 months (HbA1c fall 
<5.5mmol/mol [0.5%]) we compared HbA1c 12 months later in those who continued their 
treatment unchanged, switched to new treatment, or added new treatment.  
Results: An increase or a limited reduction in HbA1c was common, occurring in 21.9% 
(12,168/55,230), who had a mean HbA1c increase of 2.5mmol/mol (0.2%). After this limited 
response, continuing therapy was more frequent (n=9,308; 74%) than switching (n=1,177; 9%) 
or adding (n=2,163; 17%). Twelve months later, in those who switched medication HbA1c fell 
(-6.8mmol/mol [-0.6%], 95%CI -7.7, -6.0) only slightly more than those who continued 
unchanged (-5.1 mmol/mol [-0.5%], 95%CI -5.5, -4.8). Adding another new therapy was 
associated with a substantially better reduction (-12.4mmol/mol [-1.1%], 95%CI -13.1, -11.7). 
Propensity score matched subgroups demonstrated similar results. 
Conclusions: Where glucose lowering therapy does not appear effective on initial HbA1c 
testing, changing agents does not improve glycemic control. The initial agent should be 
continued with another therapy added.  
Keywords: Type 2 diabetes; oral glucose lowering medication, HbA1c, addition, switching, 
continuation, glycaemic control 
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Introduction 
Current major guidelines for type 2 diabetes suggest checking treatment response to glucose 
lowering medication with an HbA1c measurement at three to six months (1-3). What is unclear, 
is what to do if there is an apparently poor response; should this treatment be continued with 
ongoing response monitoring, should it be switched to an alternative medication, or should 
another medication be added in? To date no data from randomized controlled trials or 
observational analyses are available to address this apparently simple but clinically important 
question. Despite this national guidance in some regions has recommended discontinuation 
of therapy if a response threshold on initial HbA1c testing is not met (3).  
Data from both trials and observational studies demonstrate that there is a substantial amount 
of HbA1c variation within individuals on stable therapy over time. This variation produces a 
standard deviation (SD) of HbA1c within individuals of around 5.0 to 7.1mmol/mol (0.46 to 
0.65%) (4-6). Assuming an approximately normal distribution of HbA1c variation, one third of 
people will have an HbA1c variation greater than this SD. As most non-insulin glucose 
lowering medications reduce HbA1c by around 11.0mmol/mol (1.0%), with some variation by 
class of therapy (7-9), there will be a substantial proportion of people in whom the treatment 
effect when starting a therapy is at least partially obscured by the biological noise in HbA1c. 
Given this noise, a reasonable approach to the patient who has apparently had a limited initial 
HbA1c treatment response might be to continue the therapy unchanged; anticipating that the 
true response will become apparent over subsequent HbA1c measurements. If this hypothesis 
is correct, we would expect people who switch to another medication will have similar HbA1c 
outcomes compared with those continuing the initial therapy unchanged. We would also 
anticipate, people adding another new therapy will experience a greater HbA1c reduction than 
those who switch despite the apparent lack of effect of the first medication. If the lack of an 
initial glycemic response is a true reflection of non-response to the new medication, 
subsequent treatment switching should produce a similar response to adding another 
medication. 
We aimed to establish whether continuing, switching, or adding medication to an apparently 
ineffective glucose lowering therapy resulted in the greatest HbA1c improvement.  
Research design and methods 
We conducted a retrospective cohort analysis of 55,530 people with type 2 diabetes starting 
a second or third ever glucose lowering medication between 2004 and 2017 inclusive. We 
analysed those who had either a worsening or a limited improvement in HbA1c (HbA1c fall 
<5.5mmol/mol [0.5%]) six months after this additional glucose lowering therapy. We compared 
the subsequent glycemic outcomes in those who continued therapy unchanged, switched to 
an alternative therapy, or added an additional agent. 
Setting and participants 
We identified people with type 2 diabetes within the world’s largest longitudinal database of 
anonymized primary care electronic health records (EHR); the UK Clinical Practice Research 
Datalink (CPRD) (10). People with type 2 diabetes were identified as previously described 
(11). In brief, people with type 2 diabetes were identified from prescriptions of one or more 
glucose lowering therapies in the EHR consistent with a diagnosis of diabetes, and an age of 
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onset of diabetes (first prescription) over 35 years. People were considered not to have type 
2 diabetes if they had any diagnosis codes suggesting gestational, genetic or secondary forms 
of diabetes, polycystic ovarian syndrome, insulin as their first glucose lowering medication or 
insulin within one year of diagnosis. The date of diagnosis of diabetes was defined as the 
earlier date of the first glucose lowering medication prescription, first HbA1c value ≥48 
mmol/mol (6.5%), or first diagnosis code. Where any of these occurred within three months of 
registration with the patients’ practice, the diagnosis date was assumed to predate registration 
and the person was excluded. We did not put any restrictions on the date of diagnosis. An 
overview of study design and participant selection is shown in Figure 1. 
Identification of participants with limited initial HbA1c response to second 
and third line glucose lowering therapy 
We assessed initial HbA1c response in participants commencing second or third glucose 
lowering medication (excluding insulin) between 2004 and 2017 (inclusive) meeting the 
following criteria: New therapy taken continually for at least 6 months (based on prescriptions 
issued), pretreatment HbA1c (baseline HbA1c) >58mmol/mol (7.5%), a measure of post 
treatment HbA1c after six months (initial treatment response HbA1c), >=80% adherence to all 
prescribed glucose lowering therapy, no change in other concurrent glucose lowering therapy. 
For the baseline HbA1c we used the most recent value measured within the six months 
preceding the start of the new medication. We defined the initial treatment response HbA1c 
as the nearest HbA1c to six months (±3 months) after initiating the new therapy. Non-
adherence was defined using medication possession ratio of less than 80% (12-14). 
We defined a limited initial response to glucose lowering therapy as a worsening of HbA1c or 
an improvement of less than 5.5mmol/mol (0.5%). We did not examine people with a limited 
response to a first ever glucose lowering medication as this is most commonly metformin and 
current UK guidelines advocate dose escalation rather than treatment modification where this 
has occurred (3).  
Participant baseline characteristics 
We extracted baseline clinical characteristics at the time of medication start; age, gender, 
duration of diabetes, and body mass index (BMI), and estimated glomerular filtration rate 
(eGFR). BMI and eGFR were defined using the most recent record in the six months prior to 
the drug start date. 
Treatment choices and outcomes 
From the eligible cohort three ongoing treatment choices were defined; continue, switch, or 
add. The continue group was defined as no changes to diabetes therapies for an additional 
12 months after the initial treatment response HbA1c. The switch group was defined as people 
discontinuing their first new therapy and starting an alternative non-insulin glucose lowering 
medication within the following 12 months. The add group was defined as continuing their first 
new therapy and adding a second non-insulin glucose lowering medication within the following 
12 months. In the continue group the outcome HbA1c was defined as the closest value to 12 
months (±3 months). In the switch and add group the outcome HbA1c was defined as the 
closest value to six months (±3 months) after the medication modification. These time frames 
were selected to make the follow-up period comparable across the three groups. People 
without an outcome HbA1c were excluded. People with data fulfilling the inclusion criteria for 
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both their second and third ever medication were only included once; using data for their 
second medication only. 
Statistical methods 
We evaluated differences in baseline characteristics between the continue, switch, and add 
groups using the χ2 test for categorical variables and the unpaired t-test for continuous data. 
All reported p values are two-sided.  
Our primary analysis comprised examination of the HbA1c response to continuing, switching 
or adding, in the eligible cohort, with adjustment for baseline variables using linear regression. 
Linear regression models were adjusted for age, gender, duration of diabetes at the initiation 
of treatment, baseline HbA1c before the first medication, year of treatment, and line of therapy 
(second or third ever medication). The response to treatment choice (continue, switch or add) 
is reported with 95% confidence intervals (CI) using least-square means. Complete regression 
model results are also reported. The treatment response was defined as the change in HbA1c 
between the response HbA1c to their first new therapy (measured at 6 months) and the 
continue, switch, or add, outcome HbA1c (defined for each group as described above). 
Subgroup and sensitivity analyses 
We undertook the following subgroup analyses; separate analysis of second and third line 
therapies, a subgroup analysis of those with absolutely no reduction in initial treatment 
response HbA1c, and subgroups of treatment response to the most commonly modified 
medication classes. In the latter subgroup analyses we analyzed the impact of continuing, 
switching or adding after a limited response to sulfonylureas, thiazolidinediones (TZDs), and 
dipeptidyl peptidase-4 (DPP4) inhibitors. 
Residual confounding by characteristics influencing treatment decision could influence the 
results of our primary analysis, this is particularly important for HbA1c, as those with high 
HbA1c may be more likely to add therapy. To explore this possibility, we performed a 
sensitivity analysis in propensity score matched groups. Matching by treatment choice was 
performed to assess the two most clinically important comparisons; continue compared with 
switch and switch compared with add. Propensity score matching was performed using a 1:1 
ratio and nearest neighbor algorithm. A caliper for matching was set at 0.25 standard 
deviations (15). Variables included in the propensity matching were age, gender, duration of 
diabetes at the initiation of treatment, baseline HbA1c, and HbA1c response to the first therapy 
(change from the baseline HbA1c to the initial treatment response HbA1c).  
A second sensitivity analysis was performed, to explore the possibility of confounding by 
medication class or line of therapy, using the same group comparisons and matching variables 
as described above but with the addition of exact matching for first medication and second 
medication (for comparison of switch and add), and for line of therapy (i.e. if the first medication 
assessed was the patients second ever glucose lowering medication or their third). An initial 
caliper for matching of 0.25 standard deviations was not sufficient to remove bias in the 
propensity score matched variables following the addition of the exact matching criteria. 
Therefore, the matching caliper was progressively decreased until there was no significant 
difference between the matched groups (p>0.05) for baseline HbA1c, and HbA1c response to 
the first therapy. This approach is in accordance with previously published recommendations 
for caliper selection in 1:1 nearest neighbor propensity score matching where there is a 
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relatively small reservoir of potential matches, whereby the aim is to maximize the group size 
but minimize the risk of bias (16). 
To explore the generalisability of our results we compared the baseline characteristics of 
patients who were eligible for inclusion (i.e. those with complete outcome data and where the 
treatment decision met our definition for continue, switch, or add) with those starting a new 
second or third medication but excluded (i.e. those with missing outcome data for HbA1c or 
where the treatment decision was more complex than a simple continuation, switch, or add).  
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Results 
A fifth of people starting a second or third therapy had a limited initial HbA1c 
response 
Within CPRD 55,530 people with type 2 diabetes started a new second or third glucose 
lowering medication and had complete baseline and outcome data (Figure 1). Of these 21.9% 
(12,168) had a limited HbA1c response to this new medication in their first 6 months with a 
mean increase of 2.5mmol/mol (0.2%). In people with limited response, 8,939 (73.5%) 
continued without changes to medication, 1,119 (9.2%) switched medication, and 2,110 
(17.3%) added a new medication within the first year after the response HbA1c. Those 
continuing therapy unchanged had older age, longer diabetes duration, lower baseline HbA1c, 
and a smaller increase in HbA1c at 6 months (Table 1). When medication changes (switch or 
add) were made it tended to be early in the one year follow up window. The mean time to 
outcome HbA1c was therefore slightly longer in the continue (12.2 months; SD 2.1) compared 
to the switch (10.2 months; SD 4.5; p<0.001) and add groups (10.0 months; SD 4.5; p<0.001).  
[Table 1] 
Adding therapy led to the greatest improvement in HbA1c 
After adjustment for baseline characteristics, the mean HbA1c response to switching was 
slightly greater than the response to continuing the same therapy; -6.8 (95%CI -7.7, -6.0) 
mmol/mol (-0.6%) and -5.1 (95%CI -5.5, -4.8) mmol/mol (-0.5%) respectively (Figure 2A); 
(p<0.001).  Those adding additional therapy to an apparently ineffective therapy had the 
greatest HbA1c reduction; -12.4 (95%CI -13.1, -11.7) mmol/mol (-1.1%). 
Subgroup and sensitivity analyses 
Similar trends were also seen in the subgroups. When analyzed by line of therapy 
(Supplementary appendix 1) in those who had had a limited response to their second ever 
glucose lowering medication adding was substantially better than continuing (difference -
7.2mmol/mol [-0.7%]; 95%CI -8.0, -6.3; p<0.001) whereas switching was no better (difference 
-0.9mmol/mol [-0.1%]; 95%CI -2.1, 0.3; p=0.127). In those with a limited response to their third 
ever glucose lowing medication, adding was also substantially better than continuing 
(difference -7.5mmol/mol [-0.7%]; 95%CI -8.8, -6.1; p<0.001) whereas switching was slightly 
better (difference -3.0mmol/mol [-0.3%]; 95%CI -4.4, -1.6; p<0.001). Restricting the analysis 
to only those who had an initial worsening of their HbA1c on their new therapy again 
demonstrated the same trends although the improvement from the six-month response HbA1c 
was slightly greater in all groups (Supplementary appendix 2). 
Propensity score matched subgroups demonstrated a similar HbA1c response pattern to the 
complete cohort analysis (Figure 2B and Supplementary appendix 3). Baseline characteristics 
of the comparison groups were well balanced although there were some baseline differences 
in the medication classes used (Supplementary appendix 3). The result was unchanged when 
exact matching for line of therapy and medication class was performed (Supplementary 
appendix 4). 
We found some differences between medication classes (Figure 3 and Supplementary 
Appendix 5): Adding therapy was better than switching or continuing regardless of the original 
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therapy showing the limited response, but the greatest improvements in response were seen 
when another therapy was added to a TZD.  Switching from an SU or TZD did not result in 
improvements in response compared with continuing the original therapy, but switching from 
a DPP4 did result in a significant improvement. 
Participants eligible for inclusion in the study had similar characteristics to those excluded, 
with statistically significant but not clinically relevant differences in sex (40.4 vs 42.6% female 
in eligible vs non eligible; p<0.001), diabetes duration (5.3 vs 5.5 years; p<0.001) and baseline 
HbA1c (73.4 vs 75.7 mmol/mol; p<0.001) (Supplementary Appendix 6). 
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Discussion 
In our UK-representative cohort, more than a fifth of people with complete data met our criteria 
for a limited six-month response to a new therapy, demonstrating that this is common clinical 
scenario. Of these the most common practice was to continue the same medication over the 
following year (73.5%). People continuing and switching did demonstrate a modest 
improvement in HbA1c over the following year but neither approach improved HbA1c much 
beyond the baseline HbA1c prior to the first new therapy. Adding another new therapy to the 
apparently ineffective new therapy was the only approach which led to a clinically significant 
improvement in HbA1c. These findings were robust across different approaches to analysis. 
For TZDs switching was slightly inferior to continuing therapy unchanged and for DPP4 
inhibitors switching was substantially better than continuing. However, for each of the three 
classes (sulfonylureas, TZDs, and DPP4 inhibitors) adding another medication lead to the 
greatest HbA1c reduction, as found with the complete cohort. Our results therefore 
demonstrate that a single HbA1c measurement cannot be used to identify patients who have 
limited response to a glucose lowering therapy. Where a glucose lowering therapy does not 
appear to be effective, changing agents does not substantially improve glycemic control. The 
initial agent should therefore be continued (where that agent is tolerated) and additional 
therapy added. 
The strengths of this study include our use of multiple approaches for exploring the relationship 
between continuing, switching and adding therapies, and HbA1c outcomes in a large real-
world cohort. We have found the same trends when examined using a complete cohort with 
results adjusted for baseline characteristics, propensity score matched groups, and in 
important subgroups.  
Limitations of the study include the exclusion of people with incomplete follow up data, while 
we cannot assume generalisability to this population their similar baseline characteristics to 
those with complete follow-up data is reassuring. We had also insufficient numbers of people 
treated with some important classes of medication to examine the impact of continuing, 
switching or adding at a class level e.g. sodium glucose co-transporter-2 (SGLT2) inhibitors 
and glucagon-like peptide-1 (GLP1) analogues. This was predominately because they are 
newer medication classes and therefore less longitudinal data is currently available. As with 
all observational studies we cannot exclude residual confounding, however we have used 
multiple methods to attempt to triangulate the impact of treatment choices to reduce this 
possibility. While we have only included participants who are adherent by medication position 
ratio in our analysis, this does not fully exclude differences in adherence between treatment 
groups, as a medicine may be collected and not actually taken. A patient with side effects may 
be more likely to be non-adherent, and subsequently more likely to switch therapy. However, 
this possibility would not explain the glycaemic benefit of adding compared with switching that 
we identify, or lack of clear benefit from switching in comparison to continuing an ‘ineffective’ 
therapy. Another limitation of our study was that information on the rationale for treatment 
decision (continue, switch, or add) was not available from the dataset. 
A tendency to continue treatment unchanged in people who have not reached HbA1c targets 
(termed clinical or treatment inertia) has been reported previously (17-19). These data are 
consistent with our finding that continuing a treatment in those with a measured limited HbA1c 
response was the most common clinical practice. Our results suggest that a large proportion 
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of response variation is due to ‘noise’ – HbA1c variation related to diet or lifestyle change 
and/or measurement error, rather than innate variation in true ‘biological’ response between 
individuals. If patients with initial worsening of HbA1c were true ‘non-responders’ to therapy, 
then switching to a different therapy would be a much more effective strategy than continuing 
the same ineffective medication. In contrast our results show little difference between 
switching therapy and continuing the same medication unchanged – in other words these 
patients are obtaining underlying glucose lowering benefit from the medication, and the initial 
lack of HbA1c improvement is substantially due to chance variation in HbA1c caused by other, 
non-treatment related, factors. If HbA1c is repeated without changing therapy it will therefore 
improve due to the effects of regression to the mean (20). This is entirely consistent with 
previous studies that show very high variation of HbA1c on stable glucose lowering therapy 
(7-9). This has implications for the study and implementation of stratified, or precision 
approaches to glucose lowering therapy; while recent studies show it is possible to predict 
differences in mean glucose lowering response by patient characteristic or biomarker status 
(21-24), it may not be possible to predict a person’s response to therapy at an individual level. 
Our study is the first to examine the impact of subsequent treatment changes in people with 
an initially limited treatment response to a new glucose lowering therapy. A high quality 
randomized trial would provide valuable additional data to guide clinic practice in this common 
scenario, and may also allow assessment of whether using multiple HbA1c measures may 
allow more robust identification of poor responders to a glucose lowering therapy, something 
that is not feasible to robustly address in this dataset due to the low frequency of repeat HbA1c 
measurements in clinical care.  
Conclusion 
It is common to have a limited HbA1c response six months after starting a new glucose 
lowering medication but this is likely to represent non-treatment related HbA1c variation, rather 
than lack of biological response to a therapy.  Where a glucose lowering therapy does not 
appear to be effective on initial HbA1c testing, changing agents does not improve glycemic 
control. The initial agent should therefore be continued (where that agent is tolerated) and 
additional therapy added. 
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Tables 
 
Table 1. The characteristics of people eligible for analysis by treatment choice in the follow up 
year. 
 
Continue 
(n=8,939) 
Switch 
(n=1,119) 
Add 
(n=2,110) 
p 
Age at diagnosis (years) 57.4 (10.5) 54.8 (10.2) 55.3 (10.3) <0.001 
Female [n (%)] 3,544 (39.6) 472 (42.2) 865 (41.0) 0.175 
BMI (kg/m2) 31.5 (6.03) 33.9 (6.6) 33.5 (6.5) <0.001 
eGFR (ml/min) 77.0 (19.1) 83.4 (17.6) 82.81 (18.3) <0.001 
Diabetes duration (years) 6.2 (4.7) 5.5 (4.3) 4.9 (4.1) <0.001 
HbA1c (mmol/mol) before first new 
medication 
69.4 (10.6) 71.9 (11.1) 72.6 (11.8) <0.001 
First new medication class [n (%)]    <0.001 
   Metformin 1,951 (21.8) 109 (9.7) 302 (14.3)  
   Sulfonylureas 2,594 (29.0) 203 (18.1) 772 (36.6)  
   TZDs 2,485 (27.8) 227 (20.3) 335 (15.9)  
   Acarbose 127 (1.4) 24 (2.1) 18 (0.9)  
   Glinides 101 (1.1) 51 (4.6) 22 (1.0)  
   DPP4 inhibitors 1,514 (16.9) 447 (39.9) 597 (28.3)  
   SGLT2 inhibitors 101 (1.1) 42 (3.8) 40 (1.9)  
   GLP1 analogues 66 (0.7) 16 (1.4) 24 (1.1)  
HbA1c (mmol/mol) 6 month after first 
new medication 
71.5 (14.4) 76.2 (15.4) 77.8 (15.4) <0.001 
Change in HbA1c at 6 months 
(mmol/mol)* 
2.1 (8.3) 4.3 (9.8) 5.2 (10.0) <0.001 
Second new medication class [n (%)]    <0.001 
   Metformin N/A 25 (2.2) 62 (2.9)  
   Sulfonylureas N/A 243 (21.7) 627 (29.7)  
   TZDs N/A 248 (22.2) 621 (29.4)  
   Acarbose N/A 13 (1.2) 57 (2.7)  
   Glinides N/A 34 (3.0) 19 (0.9)  
   DPP4 inhibitors N/A 199 (17.8) 455 (21.6)  
   SGLT2 inhibitors N/A 131 (11.7) 143 (6.8)  
   GLP1 analogues N/A 226 (20.2) 126 (6.0)  
All values are expressed as mean (SD) unless otherwise stated. *A positive change in HbA1c 
equates to a deterioration. BMI = body mass index, eGFR = estimated glomerular filtration 
rate, TZD = thiazolidinedione, DPP4 = dipeptidyl peptidase-4, SGLT2 = sodium-glucose co-
transporter-2, GLP1 = glucagon-like peptide-1 
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Figure legends 
 
Figure 1. Flow diagram of patient inclusion and follow-up. *Patients failing to meet the criteria 
for continue, switch, or add had either more complex therapy changes such as adding or 
switching multiple medications in the one-year follow-up period, or had reduced adherence to 
any of the study medications. †This time window was selected to provide an outcome HbA1c 
measurement in the same time period as the response HbA1c in those switching or adding 
medications. CPRD; Clinical Practice Research Datalink. 
 
 
Figure 2. Change in HbA1c one year after a limited response to a new medication stratified 
by treatment decision after response HbA1c; continue, switch or add. A: Adjusted HbA1c 
change in the complete cohort (n=12,168). Response adjusted for age, gender, duration of 
diabetes, HbA1c at initiation of the first new therapy, year of treatment, and line of therapy 
(second or third). B: Unadjusted HbA1c in propensity score matched groups (n=3,351). 
Matched on age, gender, duration of diabetes, HbA1c at initiation of the first new therapy, and 
six-month HbA1c response to the first new therapy. 
 
 
Figure 3. Adjusted change in HbA1c one year after a limited response to a sulfonylurea 
(n=3,569) (A), thiazolidinedione (n=3,047) (B) or DPP4 inhibitor (n=2,558) (C) stratified by the 
treatment decision after response HbA1c; continue, switch or add.  
